Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Melanoma 6Breast Neoplasms 4Lymphoma, Non-Hodgkin 3Lymphoma 3Uveal Melanoma 2Neoplasms 2Mycosis Fungoides 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Renal Cell 2Carcinoma 2Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Neoplasm Metastasis 1Mycoses 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × ProMune × Clear all
NCT00199836 2022-10-10

A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and MontanideĀ® ISA-51 in Patients With Cancer.

Ludwig Institute for Cancer Research

Phase 1 Completed
14 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT00031278 2011-05-30

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Pfizer

Phase 1/2 Completed
12 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔